ENHA · NYSE · Financial - Conglomerates

Enhanced Group

Operates performance-enhancement-permitted sports events alongside telehealth protocols and wellness supplements.

$1.64
After-hours close+0.01 (+0.92%)
At close$1.63(+2.85%)
Loading prices…

Profile

Enhanced Group Inc. Class AENHAFinancials

Combines a performance-enhancement-permitted sports property with U.S. telehealth and supplement sales, using the Games as an audience and brand engine for Live Enhanced. Intended revenue spans media, sponsorship, licensing and consumer wellness purchases, while clinical decisions and fulfillment sit with partners.

Runs the Enhanced Games, a performance-enhancement-permitted sports-entertainment property spanning live competition, media, sponsorships and licensed consumer products. It owns the event and brand intellectual property while partners handle production and content distribution; athlete stories and audience attention are intended to support sponsorship, media-rights, merchandise and licensing revenue.

Operates Live Enhanced, a U.S.-focused direct-to-consumer platform for clinician-guided prescription protocols and non-prescription supplements. It manages the customer-facing site, retail prices, marketing and non-clinical communication, while independent clinicians determine prescriptions and partner pharmacies fulfill approved care.

Relies on outside providers for clinical services, fulfillment, manufacturing, venues, production and distribution. Prescription protocols depend on state and federal rules governing medical practice, licensure, marketing, pharmacy fulfillment and data privacy. Its dual-class share structure gives Apeiron, executive chairman Christian Angermayer's investment group, decisive influence over director elections and major corporate actions.

Company facts

CEOMaximilian Martin
ListedMay 8, 2026
ExchangeNYSE
HeadquartersNew York, NY
CountryUnited States
Employees26
CIK0001956439
ISINUS29333R1077

Key statistics

Market cap$208.4M
EPS (ttm)−$0.1177
P/E (ttm)−13.76
ROE-85.6%
P/B7.88
P/S75,653.23
Dividend yield
Beta

Year to date −84.2% · Average volume (30d) 923.6K

Analysts

No analyst consensus on record.

Earnings

EPS

Estimate−$0.03
ReportedDue Nov 12, 2026

Revenue

Estimate$10.2M
ReportedDue Nov 12, 2026

History

Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseNext session
Aug 13, 2026−$0.18−$0.44−144.4%$24.6M$17.7M−28.0%−21.60%
Jun 3, 2026Q1 FY26−$0.14−$0.140.0%$2.9K$2.9K0.0%−5.73%
May 4, 2026Q1 FY26−$0.14−$0.13+7.1%$2.9K$1.5K−48.3%−3.68%
Feb 9, 2026Q4 FY25$0.01$303.5K
View details

Financial highlights

4 quartersQ2 FY25Q3 FY25Q4 FY25Q1 FY26
Revenue$0$0$0$2.8K
Gross profit$0$0$0$2.8K
Operating income−$2.3K−$22.2K−$104.4K−$16.5M
Net income−$2.3K$189.1K$146.8K−$16.4M
Diluted EPS$0.00$0.01$0.01−$0.13
Gross margin100.0%
Operating margin-600,410.5%

Balance sheet, Mar 31, 2026Cash & short-term investments $54.6K · Total debt $0 · Total assets $26.2M · Shareholders' equity $25.1M

Dividends

No dividends on record.

Ownership

Institutions 9.46%Insiders

Shares outstanding 128.66M · Float 64.85M · 50.4% free float

Top shareholders13F · 13D/G · Form 4

HolderShares% outstandingFormFiled
Davidson Kempner Capital Management LP1.29M1.00%13FAug 14, 2026
LMR Partners LLP1.29M1.00%13FAug 14, 2026
Anson Funds Management LP1.29M1.00%13FAug 13, 2026
Citadel Advisors LLC1.29M1.00%13FAug 14, 2026
BlackRock, Inc.1.05M0.82%13FAug 7, 2026

Insider tradesForm 4

Nothing filed in the last 12 months.

View details

Peers

  • Hims & Hers Health

    Dominant DTC rival in hormones, weight loss and longevity.

  • LifeMD

    DTC protocol rival in TRT, hormone care and GLP-1 weight loss.

  • TKO Group

    Large live-sports rival for athletes, media rights and sponsors.

  • WeightWatchers

    Direct GLP-1 access rival in clinician-guided weight management.

CompareAfter-hours close

CompanyPriceChange
Enhanced Group$1.64+0.92%$208.4M75,653.2
Hims & Hers Health$28.86+0.10%$6.43B110.62.5+38.3%
LifeMD$3.20+1.74%$151.9M0.7−24.0%
TKO Group$185.76+0.63%$13.84B63.733.12.6+18.2%
WeightWatchers$16.40+1.17%$162.0M0.2
Median63.771.81.6+18.2%